Universal Health Services (UHS)
(Delayed Data from NYSE)
$205.26 USD
+0.95 (0.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.26 USD
+0.95 (0.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook
by Zacks Equity Research
Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.
Brookdale (BKD) February 2024 Weighted Average Occupancy Rises
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 28 months of year-over-year improvements in the weighted average occupancy level.
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
by Zacks Equity Research
The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.
Are Investors Undervaluing Universal Health Services (UHS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ensign Group (ENSG) Up 30.8% in 6 Months: More Growth Ahead?
by Zacks Equity Research
Ensign Group's (ENSG) growing strength in its Skilled Services business is a major upside.
Humana (HUM) Inks Value-Based Deal to Offer Better Kidney Care
by Zacks Equity Research
Humana (HUM) expands ties with Strive to offer high-quality kidney care to its Medicare Advantage members and thereby, aims to increase the customer base of the relevant business line.
Looking for a Growth Stock? 3 Reasons Why Universal Health Services (UHS) is a Solid Choice
by Zacks Equity Research
Universal Health Services (UHS) possesses solid growth attributes, which could help it handily outperform the market.
HCA Healthcare (HCA) Rises 24.8% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare's (HCA) growing equivalent admissions are supporting performance.
Here's Why Universal Health Services (UHS) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services and Tenet Healthcare
by Zacks Equity Research
HCA Healthcare, Universal Health Services and Tenet Healthcare have been highlighted in this Industry Outlook article.
Can Universal Health Services (UHS) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Universal Health Services (UHS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Universal Health Services (UHS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Stocks Worth a Deeper Dive in the Thriving Hospital Industry
by Kaibalya Pravo Dey
Following a careful analysis of the Zacks Medical-Hospital industry, we advise focusing on companies like HCA, UHS and THC.
Universal Health Services (UHS) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Universal Health (UHS) Q4 Earnings Beat on Adjusted Admissions
by Zacks Equity Research
Universal Health (UHS) expects net revenues between $15.411 billion and $15.706 billion for 2024, which indicates 8.9% year-over-year growth.
Compared to Estimates, Universal Health Services (UHS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Universal Health Services (UHS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 3.64% and 1.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cooper Companies (COO) in Q1 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Should You Buy Universal Health (UHS) Ahead of Earnings?
by Zacks Equity Research
Universal Health (UHS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.
Ahead of Universal Health Services (UHS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Universal Health Services (UHS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.